How should steroid‑induced hyperglycemia be screened and managed in outpatient adults, particularly those over 45 years old, overweight/obese, or with diabetes risk factors?

Management of Steroid-Induced Hyperglycemia in Outpatient Adults

Screen all outpatients starting glucocorticoids with capillary blood glucose measurements taken pre-breakfast and pre-evening meal (or 7-9 hours post-dose for prednisone/dexamethasone), and diagnose steroid-induced hyperglycemia when two random blood glucose readings are ≥11.1 mmol/L (200 mg/dL) on different occasions. 1

Risk Stratification and Screening

Who to Screen

• All patients starting glucocorticoids should be screened, regardless of baseline diabetes status 1
• High-risk patients include those with newly detected hyperglycemia, elevated HbA1c, or pre-existing type 2 diabetes 1
• Moderate-risk patients include those commencing corticosteroids with raised lipase 1
• Patients over 45 years, overweight/obese (BMI ≥25 kg/m²), or with diabetes risk factors require more intensive monitoring 2, 3

Baseline Assessment Before Starting Steroids

• Measure HbA1c to identify undiagnosed pre-existing diabetes 1
• Obtain fasting blood glucose if HbA1c ≥5.7% (39 mmol/mol) 3
• Critical distinction: Pre-treatment HbA1c ≥6.5% indicates pre-existing diabetes that will persist after steroid discontinuation, requiring different management 4, 5

Monitoring Strategy

• Timing is critical: Prednisone causes peak hyperglycemia 8 hours post-dose (late morning/afternoon); dexamethasone peaks at 7-9 hours 1
• Fasting glucose alone is inadequate and will miss most cases 1, 6
• Check capillary blood glucose pre-breakfast and pre-evening meal daily during steroid therapy 5
• For moderate-risk patients, measure 2-hour postprandial or 8-hour post-prednisone serum glucose at clinic visits 1
• 20% of patients develop glucose intolerance despite normal fasting glucose, particularly those ≥50 years old 4

Diagnosis

Persistent hyperglycemia with two abnormal tests (random blood glucose ≥11.1 mmol/L on different occasions and/or newly elevated HbA1c ≥6.5%) plus corticosteroid use establishes the diagnosis of steroid-induced diabetes. 1

Treatment Algorithm

Mild Hyperglycemia (Random glucose 11.1-15 mmol/L)

Start with oral agents:

• Gliclazide (sulfonylurea) as first-line for isolated daytime hyperglycemia 1, 7
• Add metformin if renal and hepatic function preserved (metformin may alleviate some metabolic effects of steroids) 1
• Warn patients about hypoglycemia risk with sulfonylureas 1
• DPP-4 inhibitors or GLP-1 receptor agonists can be considered as second-line if pancreatitis and elevated lipase are absent 1

Moderate Hyperglycemia (Random glucose 15-20 mmol/L)

Initiate intermediate-acting insulin:

• NPH (isophane) insulin given once in the morning matches the afternoon hyperglycemia pattern from morning prednisone 1, 7
• Starting dose: 0.1-0.3 units/kg/day, adjusted based on steroid dose 1, 8
• For dexamethasone: Consider NPH insulin twice daily (2/3 morning dose, 1/3 early evening) for more flexibility 8
• Avoid basal-bolus regimens in de novo steroid-induced diabetes due to nocturnal hypoglycemia risk 7

Severe Hyperglycemia (Random glucose >20 mmol/L or >15 mmol/L persistently)

Basal-bolus insulin regimen:

• Start at 0.3-0.5 units/kg/day, split 50/50 between basal (glargine once daily) and rapid-acting insulin (with each meal) 1
• Alternative for patients struggling with multiple injections: Mixed insulin (e.g., Novomix 30) given in the morning 1
• Long-acting basal insulin (glargine) is non-inferior to intermediate insulin and useful for prolonged glucose elevation 1

Critical Management Principles

Patient Education

• Educate on glucose monitoring, symptoms of severe hyperglycemia, and when to seek emergency care 1
• Teach hypoglycemia recognition and management for those on sulfonylureas or insulin 1
• Emphasize that steroid dose adjustments require diabetes treatment adjustments 1

Dose Adjustments

• Hyperglycemia degree correlates with steroid dose 1
• When steroids are tapered, rapidly reduce or discontinue diabetes medications to prevent hypoglycemia 8, 7
• Monitor closely during steroid dose changes 1

Pre-existing Diabetes

• Patients with pre-existing type 2 diabetes will require intensification of their existing regimen 1
• Those already on insulin often need basal-bolus therapy during high-dose steroid treatment 8
• Diabetes will persist after steroid discontinuation in these patients 1

Common Pitfalls to Avoid

• Do not rely on fasting glucose alone—it misses the characteristic afternoon hyperglycemia pattern 1, 4, 6
• Do not use basal-bolus insulin for new-onset steroid-induced diabetes—it causes nocturnal hypoglycemia without covering afternoon peaks 7
• Do not forget to check baseline HbA1c—distinguishing pre-existing from new-onset diabetes changes long-term management 4, 5
• Do not continue aggressive diabetes treatment after steroid discontinuation—hypoglycemia risk is high 8, 7
• Avoid SGLT2 inhibitors in acute settings due to ketoacidosis risk 8
• Sulfonylureas are not recommended for inpatient dexamethasone-induced hyperglycemia 8

Follow-up Duration

• Monitor for 12 months after steroid initiation, as hyperglycemia can develop even months later 1
• After 12 months, transition to standard type 2 diabetes screening with primary care if diabetes persists 1
• In patients without pre-existing diabetes, steroid-induced diabetes may resolve after steroid discontinuation, but some convert to type 2 diabetes 1